Formulation Development
Lilly Receives MHRA Marketing Authorisation for Abemaciclib in Combination With Endocrine Therapy for Adjuvant Treatment of People With HR+, HER2- High-Risk Early Breast Cancer
Eli Lilly and Company recently announced the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for abemaciclib in combination with endocrine…
Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award
For the third year in a row, Vetter has won the Best Managed Companies Award. With this three-win feat, the pharmaceutical service provider has once again…
4D pharma Presents Late-Breaking Abstract From Phase 1/2 Trial of MRx-4DP0004 for the Treatment of Asthma
4D pharma plc recently announced the presentation of a late-breaking poster on data from Part A of the Phase 1/2 trial of MRx-4DP0004 for the…
IN8bio Announces Data Emerging From its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio, Inc. recently announced data emerging from the company’s recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches…
Codiak Presents New Preclinical Data on Exosome-Based Strategy to Enhance AAV Gene Therapy
Codiak BioSciences, Inc. recently announced new preclinical data on the company’s engEx-AAV discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene….
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of a Selective BTK Degrader in Development for B-cell Leukemias & Lymphomas
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent…
Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time & Accelerate Path to Clinic
Catalent recently introduced its new, UpTempo Virtuoso platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes…
Prota Therapeutics Achieves 51% Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared With Standard Care
Prota Therapeutics Pty Ltd is the first company to validate significant Health-Related Quality of Life improvements (HRQL), when compared to placebo, in a Phase 2b…
Travere Therapeutics Announces FDA Acceptance & Priority Review of NDA for Sparsentan for the Treatment of IgA Nephropathy
Travere Therapeutics, Inc. recently announced the US FDA has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated…
Akston Biosciences Doses First Participants in Phase 2 Clinical Trial for Shelf-Stable COVID-19 Booster
Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a…
Pneumagen Announces Positive Top Line Results From Phase 1 Study Evaluating a Product Designed for the Prevention & Treatment of Viral Respiratory Tract Infections
Pneumagen recently reported positive topline data from a Phase 1 study with Neumifil designed to evaluate safety and tolerability in healthy volunteers. The Phase 1, single…
NGM Bio Announces Initiation of Phase 1/1b Clinical Study for the Treatment of Patients With Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. recently announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. With…
Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..
Vallon Pharmaceuticals Reports Additional Pharmacokinetic & Pharmacodynamic Data From SEAL Study of ADAIR
Vallon Pharmaceuticals, Inc. recently reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the company’s proprietary abuse-deterrent formulation of…
Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Artax Biopharma, Inc. recently announced the close of a $26-million financing round to develop AX-158, the company’s first oral small molecule immunomodulating agent…..
Cue Biopharma Receives FDA Acceptance of IND Application for CUE-102 in Wilms’ Tumor 1 (WT1) - Expressing Cancers
Cue Biopharma, Inc. recently announced the US FDA has accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin…
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients With Advanced Solid Tumors
Immatics N.V. recently announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER) IMA401 for patients with recurrent and/or refractory….
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Faraday Pharmaceuticals, Inc. recently announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy…
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial
Evaxion Biotech A/S recently announced it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial…
AUM Biosciences Enters Collaboration With Roche for Clinical Development of AUM001 in Combination With Anti-PD-L1 Therapy in Solid Tumor Indications
AUM Biosciences recently announced it has entered into a clinical trial collaboration and supply agreement with Roche to evaluate AUM001, the company’s novel, highly selective….
